These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 12925557)

  • 21. Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM.
    Penno G; Chaturvedi N; Talmud PJ; Cotroneo P; Manto A; Nannipieri M; Luong LA; Fuller JH
    Diabetes; 1998 Sep; 47(9):1507-11. PubMed ID: 9726242
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Polymorphism of the ACE gene, structural-functional state of the left ventricle in patients with post-infarction cardiac failure and effects of the ACE-inhibitor Perindopril].
    Tereshchenko SN; Demidova IV; Kobalava ZhD; Moiseev VS
    Ter Arkh; 2002; 74(4):56-8. PubMed ID: 12043242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relation between the angiotensin-converting enzyme insertion/deletion polymorphism and blood pressure in Japanese male subjects.
    Todoroki M; Minami J; Ishimitsu T; Ohrui M; Matsuoka H
    J Hum Hypertens; 2003 Oct; 17(10):713-8. PubMed ID: 14504630
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Perindopril Protection Against Recurrent Stroke Study (PROGRESS): clinical implications for older patients with cerebrovascular disease.
    Ratnasabapathy Y; Lawes CM; Anderson CS
    Drugs Aging; 2003; 20(4):241-51. PubMed ID: 12641480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of a perindopril-based blood pressure-lowering regimen on disability and dependency in 6105 patients with cerebrovascular disease: a randomized controlled trial.
    Fransen M; Anderson C; Chalmers J; Chapman N; Davis S; MacMahon S; Neal B; Sega R; Terent A; Tzourio C; Woodward M;
    Stroke; 2003 Oct; 34(10):2333-8. PubMed ID: 12958329
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials.
    Brugts JJ; Ninomiya T; Boersma E; Remme WJ; Bertrand M; Ferrari R; Fox K; MacMahon S; Chalmers J; Simoons ML
    Eur Heart J; 2009 Jun; 30(11):1385-94. PubMed ID: 19346520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiotensin-converting enzyme gene insertion/deletion, not bradykinin B2 receptor -58T/C gene polymorphism, associated with angiotensin-converting enzyme inhibitor-related cough in Chinese female patients with non-insulin-dependent diabetes mellitus.
    Lee YJ; Tsai JC
    Metabolism; 2001 Nov; 50(11):1346-50. PubMed ID: 11699055
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Association of insertion/deletion polymorphism in angiotensin-converting enzyme gene with hypertensive type 2 diabetes mellitus].
    Zhou L; Xue YM; Luo R; Gao F
    Di Yi Jun Yi Da Xue Xue Bao; 2002 Sep; 22(9):808-10. PubMed ID: 12297438
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiotensin converting enzyme insertion/deletion polymorphism and short-term renal response to ACE inhibition: role of sodium status.
    van der Kleij FG; Schmidt A; Navis GJ; Haas M; Yilmaz N; de Jong PE; Mayer G; de Zeeuw D
    Kidney Int Suppl; 1997 Dec; 63():S23-6. PubMed ID: 9407415
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of angiotensin converting enzyme gene insertion/deletion polymorphism with lung cancer in Turkey.
    Nacak M; Nacak I; Sanli M; Ozkur M; Pektaş M; Aynacioğlu AS
    Cancer Genet Cytogenet; 2010 Apr; 198(1):22-6. PubMed ID: 20303010
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiotensin I-converting enzyme gene polymorphism and acute response to captopril in essential hypertension.
    Nakano Y; Oshima T; Watanabe M; Matsuura H; Kajiyama G; Kambe M
    Am J Hypertens; 1997 Sep; 10(9 Pt 1):1064-8. PubMed ID: 9324115
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of risk factors for the development of nephropathy in patients with IDDM: insertion/deletion angiotensin converting enzyme gene polymorphism, hypertension and metabolic control.
    Barnas U; Schmidt A; Illievich A; Kiener HP; Rabensteiner D; Kaider A; Prager R; Abrahamian H; Irsigler K; Mayer G
    Diabetologia; 1997 Mar; 40(3):327-31. PubMed ID: 9084972
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Renin angiotensin system blockage associates with insertion/deletion polymorphism of angiotensin-converting enzyme in patients with hypertensive emergency.
    Vilela-Martin JF; Vaz-de-Melo RO; Cosenso-Martin LN; Kuniyoshi CH; Yugar-Toledo JC; Pinhel MA; de Souza GF; Souza DR; Pimenta E; Moreno H; Cipullo JP
    DNA Cell Biol; 2013 Sep; 32(9):541-8. PubMed ID: 23869738
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [PROGRESS].
    Hasegawa Y
    Nihon Rinsho; 2006 Aug; 64 Suppl 6():396-401. PubMed ID: 16983776
    [No Abstract]   [Full Text] [Related]  

  • 35. Blood pressure lowering, not vascular mechanism of action, is the primary determinant of clinical outcome.
    Leenen FH
    Can J Cardiol; 2004 Aug; 20 Suppl B():77B-82B. PubMed ID: 15309209
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interaction between angiotensin-converting enzyme gene insertion/deletion polymorphism and angiotensin-converting enzyme inhibition on survival in hemodialyzed patients.
    Kiss I; Ambrus C; Kulcsár I; Szegedi J; Kerkovits L; Tislér A; Kiss Z;
    Medicine (Baltimore); 2014 Dec; 93(28):e315. PubMed ID: 25526485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angiotensin-converting enzyme insertion/deletion polymorphism has no effect on the risk of atherosclerotic stroke or hypertension.
    Tascilar N; Dursun A; Ankarali H; Mungan G; Ekem S; Baris S
    J Neurol Sci; 2009 Oct; 285(1-2):137-41. PubMed ID: 19596363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ACE DD genotype is more susceptible than ACE II and ID genotypes to the antiproteinuric effect of ACE inhibitors in patients with proteinuric non-insulin-dependent diabetes mellitus.
    Ha SK; Yong Lee S; Su Park H; Ho Shin J; Jung Kim S; Hun Kim D; Rae Kim K; Yung Lee H; Suk Han D
    Nephrol Dial Transplant; 2000 Oct; 15(10):1617-23. PubMed ID: 11007831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition.
    Hingorani AD; Jia H; Stevens PA; Hopper R; Dickerson JE; Brown MJ
    J Hypertens; 1995 Dec; 13(12 Pt 2):1602-9. PubMed ID: 8903618
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Polymorphism studies of angiotensin converting enzyme gene in chronic glomerulonephritis].
    Kutyrina IM; Tareeva IE; Nosikov VV; Kamyshova ES; Gorashko NM; Chistiakov DA; Okonova EB; Troepol'skaia OV
    Ter Arkh; 1999; 71(6):30-4. PubMed ID: 10420452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.